Document Detail

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
MedLine Citation:
PMID:  23055389     Owner:  NLM     Status:  MEDLINE    
Cetuximab (Erbitux(®)) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid]). The addition of cetuximab to first-line treatment with FOLFIRI improved progression-free survival, overall survival, and objective response rates relative to treatment with FOLFIRI alone in patients with EGFR-expressing mCRC with KRAS wild-type tumors. Therefore, cetuximab plus FOLFIRI is a useful biomarker-directed option in the first-line treatment of this patient population.
Katherine A Lyseng-Williamson
Related Documents :
2853509 - Clinical evaluation of focal excision of myometrial lesion for treatment of invasive hy...
24046519 - Totally laparoscopic distal gastrectomy with d2 lymphadenectomy and billroth ii gastroj...
2258069 - Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases.
18534669 - Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiothera...
22526899 - Decreasing rates of lymph node dissection during radical nephrectomy for renal cell car...
1444199 - Clinical stage i and ii endometrial carcinoma: multivariate analysis of prognostic fact...
21586749 - Flt3/itd aml and the law of unintended consequences.
10036659 - The significance of dna flow cytometry in predicting survival and delayed clinical mani...
17141809 - Tissue distribution evaluation of stealth ph-sensitive liposomal cisplatin versus free ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  16     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-03-28     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  317-22     Citation Subset:  IM    
Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / analogs & derivatives,  therapeutic use
Colorectal Neoplasms / drug therapy*,  pathology
Disease-Free Survival
Fluorouracil / therapeutic use
Gene Expression Regulation, Neoplastic
Guidelines as Topic
Leucovorin / therapeutic use
Neoplasm Metastasis
Proto-Oncogene Proteins / genetics,  metabolism
Receptor, Epidermal Growth Factor / antagonists & inhibitors,  genetics,  metabolism
ras Proteins / genetics,  metabolism
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/KRAS protein, human; 0/Proto-Oncogene Proteins; 51-21-8/Fluorouracil; 58-05-9/Leucovorin; 7689-03-4/Camptothecin; EC, Epidermal Growth Factor; EC Proteins; PQX0D8J21J/cetuximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas.
Next Document:  Large enhancement of oscillating chemiluminescence with [Ru(bpy)(3) ](2+) -catalyzed Belousov-Zhabot...